Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study to Determine How and Why HIV-Infected Subjects on Anti-Viral Treatment Develop Lipodystrophy
This study has been completed.
Study NCT00006190 Information provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First Received: August 25, 2000 Last Updated: August 2, 2007
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Lipodystrophy
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Infection
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Lipid Metabolism Disorders
Metabolic Diseases
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Skin Diseases
Skin Diseases, Metabolic
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Nelfinavir mesylate
Stavudine
Lamivudine
Efavirenz
Additional drug interventions recognized in this trial
Nelfinavir
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antimetabolites
Antiviral Agents
Enzyme Inhibitors
HIV Protease Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Protease Inhibitors
Reverse Transcriptase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Back to top of Main Content
